Health Care Stocks: Check Out This Low-Cost Market Beater

These health care stocks have been growing by double digits. Should you buy?

Apr 15, 2014 at 5:15PM

Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you. If you'd like to add some health care stocks to your portfolio but don't have the time or expertise to hand-pick a few, the iShares US Healthcare ETF (NYSEMKT:IYH) could save you a lot of trouble. Instead of trying to figure out which health care stocks will perform best, you can use this ETF to invest in lots of them simultaneously.

The basics
ETFs often sport lower expense ratios than their mutual fund cousins. This ETF, focused on health care stocks, sports a relatively low expense ratio -- an annual fee -- of 0.46%.

The iShares US Healthcare ETF has outperformed the world market over the past five and 10 years. As with most investments, of course, we can't expect outstanding performances in every quarter or year. Investors with conviction need to wait for their holdings to deliver.

Why health care stocks?
For starters, the world's growing and aging population will keep demand rising for health care products and services. On top of that, Obamacare is ushering more Americans into health coverage, bringing health care companies more customers -- and thereby boosting the prospects of their stocks.

More than a handful of health care stocks had strong performances over the past year. Regeneron Pharmaceuticals (NASDAQ:REGN), for example, surged 34%, partly on the success of its wet age-related macular degeneration drug, Eylea, which generated close to $2 billion in sales last year and may gain approval to tackle other eye issues, too. Regeneron's pipeline has a lot of potential, including its PCSK9 inhibitor, alirocumab, which is faring well in Japanese trials. The stock is not a slam-dunk, though, as there's able competition, and its valuation isn't exactly cheap. Regeneron reports its first-quarter results on May 8.

Biogen Idec (NASDAQ:BIIB) jumped 32%. The company is enjoying strong sales of its multiple sclerosis drug Tecfidera, while also gaining Food and Drug Administration approval for its developmental hemophilia B treatment, Alprolix. In its last quarter, earnings popped 56%, with Tecfidera sales approaching $400 million. The company's pipeline holds much promise, with additional treatments for hemophilia and MS, for example.

Gilead Sciences (NASDAQ:GILD) gained 27%. Its recently approved oral hepatitis C treatment, Sovaldi, has blockbuster potential and is off to a strong start, but many are balking at its steep price tag of around $84,000 for a 12-week course. Sales of Gilead's HIV drug Stribild are growing rapidly,  and it might achieve blockbuster status soon, too. (Gilead is a leader in HIV treatments, which generate much of its revenue.) The company's fourth quarter was strong, in large part due to new products -- which is good for a drug company, as patent expirations limit the value of older drugs. With a forward price-to-earnings ratio near 11, the stock is worth considering.

Other health care stocks didn't do quite so well over the last year but could see their fortunes change in years to come. Celgene Corporation (NASDAQ:CELG), another biotech concern, tacked on 11%. It's on a roll, thanks in part to its anemia drug, Revlimid, with many hopeful about its recently approved arthritis drug, Otezla, too. Celgene is investing heavily in other companies with promising early-stage drugs, a move that could pay off handsomely in many years, not months. As my colleague Stephen Simpson has noted, Celgene has "a deep early stage pipeline of oncology drugs" and "meaningful label expansion opportunities for approved drugs." It appears to be undervalued, too, with its forward P/E ratio near 15.

The big picture
If you're interested in adding some health care stocks to your portfolio, consider doing so via an ETF. A well-chosen ETF can grant you instant diversification across any industry or group of companies -- and make investing in and profiting from it that much easier.

Top dividend stocks for the next decade
The smartest investors know that dividend stocks simply crush their non-dividend-paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.

Selena Maranjian, whom you can follow on Twitter, owns shares of Celgene, Gilead Sciences, and Regeneron Pharmaceuticals. The Motley Fool recommends Celgene and Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information